NEW YORK (GenomeWeb News) – Pacific Biosciences today announced an agreement with Roche Diagnostics to develop diagnostic products based on PacBio's SMRT technology.
Including upfront, milestone, and supply payments, the deal is potentially worth more than $75 million to PacBio.